Superworth

Arcus Biosciences free cash flow RCUS

Cash from operations less capital spending, by quarter and over the last twelve months, from 2017.

Last 12 months, to Jun 30, 2026
−$475M
Latest quarter, Q2 FY26
−$119M
Fiscal year 2025
−$484M

Arcus Biosciences' free cash flow was −$475M over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$119M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025−$484Mn/a
FY2024−$176Mn/a
FY2023−$330M−176%
FY2022$432Mn/a
FY2021−$282.2M−361%
FY2020$108.1Mn/a
FY2019−$75.4Mn/a
FY2018−$46.7Mn/a
FY2017−$30.6Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q2 FY26−$119Mn/a−$475M
Q1 FY26−$138Mn/a−$489M
Q4 FY25−$121Mn/a−$484M
Q3 FY25−$97M−488%−$464M
Q2 FY25−$133Mn/a−$342M
Q1 FY25−$133Mn/a−$303M
Q4 FY24−$101Mn/a−$176M
Q3 FY24$25Mn/a−$169M
Q2 FY24−$94Mn/a−$267M
Q1 FY24−$6Mn/a−$235M
Q4 FY23−$94Mn/a−$330M
Q3 FY23−$73Mn/a−$306.1M

Against its peers

Companies in Drug Manufacturers - General nearest Arcus Biosciences' size, closest first, today.

CompanyFree cash flow yield
RCUSArcus Biosciences−20.1%
PBHPrestige Consumer Healthcare10.4%
HRMYHarmony Biosciencesn/m
NRIXNurix Therapeutics13.4%
ANIPANI Pharmaceuticals10.4%
PAHCPhibro Animal Health0.6%
OGNOrganon15.7%
LQDALiquidia3.9%
ANABAnaptysbion/m
PCRXPacira BioSciences12.4%
ARQTArcutis Biotherapeutics1.0%
Peer median10.4%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Arcus Biosciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.